The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Checkpoint inhibitor combination approaches for AML/MDS: an update
Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives us an update on promising checkpoint inhibitor combination approaches for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
